SENSEX NIFTY
Jun 06, 2012, 02.08 PM IST | Source: Reuters

Merck KGaA, Dr. Reddy's to cooperate on biosimilars

DRREDDYSLABORATORIES-BRIEF:Merck KGaA, Dr. Reddy's to cooperate on biosimilars

FRANKFURT (Reuters) - German pharmaceutical company Merck KGaA and India's Dr. Reddy's Laboratories Ltd announced plans to jointly develop biosimilar versions of biotech cancer drugs.

The deal is the latest example of drug companies jumping into a new space that is opening up as patents on biotech medicines expire.

"Sharing know-how, risks and rewards is the right approach to enter the emergent biosimilars market and will be a win-win for both parties," Merck executive board member Stefan Oschmann said in a statement on Wednesday.

Under the agreement, Merck and Dr. Reddy's will co-develop molecules and Dr. Reddy's will lead early product development and testing.

Merck will manufacture the compounds and lead late-stage development. It will also handle commercialisation in large parts of the world and will pay Dr. Reddy's royalties.

(Reporting by Maria Sheahan)

ADS BY GOOGLE

video of the day

Risk is a four letter word: Author Jerome Booth

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.